Drug Profile
Vibegron - Kyorin Pharmaceutical/Sumitomo Pharma America
Alternative Names: Beova; GEMTESA; KRP-114V; KRP-114VP; MK-4618; RVT 901; SNV-004; URO 901Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Kyorin Pharmaceutical; Merck & Co; Sinovant Sciences; Sumitomo Pharma America
- Class Amides; Analgesics; Pyrimidines; Pyrroles; Pyrrolidines; Small molecules; Urologics
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Overactive bladder
- Phase II/III Neurogenic bladder
- Phase II Pain
- Discontinued Endocrine disorders
Most Recent Events
- 13 Sep 2023 Efficacy and adverse events data from a phase III URO-901-3006 extension trial in Overactive bladder released by Sumitomo Pharma
- 11 Sep 2023 Efficacy and adverse events data from a phase III URO-901-3005 trial in Overactive bladder released by Sumitomo Pharma
- 23 Jun 2023 Phase-III clinical trials in Overactive bladder in China (PO) (Sumitomo Pharma pipeline, June 2023)